Scandinavian ChemoTech AB is carrying out another directed new share issue and will receive approximately MSEK 2.5

Scandinavian ChemoTech AB (publ) (“ChemoTech” or “the Company”) hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 2.5. The capital injection will be used to repay loans.

The Board of ChemoTech has, with the support of authorisation from the Annual General Meeting on May 24, 2021, decided on a directed new issue of 121,417 Series B shares at the same terms and conditions as the previously closed directed share issue which provided the Company with approximately MSEK 18. Thus, the subscription price amounts to SEK 20.59 per share. The right to subscribe for the new shares shall vest in the lenders Qualcon Aktiebolag which has subscribed for 97,134 shares and Råsunda Förvaltning Aktiebolag which has subscribed for 24,283 shares.

It is the Board's assessment that the subscription price is market-based and reflects prevailing market conditions and demand. The reason why the share issue has been carried out, and the reasons for the deviation from the shareholders' preferential rights is that it provides the company with working capital in a sufficiently time- and cost-effective manner and take advantage of future opportunities to bring in long-term stable owners and finance the Company’s growth strategy.

The directed share issue issues a dilution of approximately 1.26 percent of the number of shares and approximately 1.04 percent of the votes in the Company calculated according to the directed share issue. Following the registration of the directed share issue with the Swedish Companies Registration Office, the total number of outstanding shares will increase by 121,417, from 9,507,638 to 9,629,055 and the number of votes will increase by 121,417, from 11,607,638 votes to 11,729,055 votes. The share capital will increase by SEK 60,708.50, from 4,753,819.00 to 4,814,527.50.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-09-2021 21:30 CET.

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.